<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158820</url>
  </required_header>
  <id_info>
    <org_study_id>810981</org_study_id>
    <nct_id>NCT01158820</nct_id>
  </id_info>
  <brief_title>Alternative Sedation During Bronchoscopy</brief_title>
  <acronym>DEX</acronym>
  <official_title>A Randomized, Placebo-controlled, Concealed Allocation Comparison of Respiratory Depression and Coughing During Bronchoscopy With Dexmedetomidine-ketamine as an Adjunct to Fentanyl-midazolam Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the
      use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in
      less respiratory depression while providing better compliance with the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients enrolled in the study will be undergoing bronchoscopy, which is typically
      performed with sedation. All procedural sedation carries some risk. Several features of the
      study may lower the risk of sedation relative to that of conventional sedation. An
      anesthesiologist will be present throughout the procedure. Continuous monitoring of
      respiration with RIP will be employed. Administration of sedation will be via a volumetric
      syringe pump. Benefits specific to dexmedetomidine-ketamine include the lack of respiratory
      depression and greater hemodynamic stability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased Minute Ventilation</measure>
    <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
    <description>An initial baseline minute ventilation estimate was obtained via calibrated respiratory impedance plethysmography bands. Subsequent minute ventilation was normalized to this value. Values exceeding 100% were excluded from analysis, as these typically reflected a period of hyperpnea subsequent to relief of airway obstruction by chin lift or jaw thrust.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Fentanyl</measure>
    <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
    <description>Total fentanyl dose delivered during the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Midazolam</measure>
    <time_frame>Duration of procedure</time_frame>
    <description>Total midazolam delivered during procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Desaturation (Cumulative)</measure>
    <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
    <description>Cumulative time below saturation of 90% - the total number of seconds that the pulse oximeter reported a saturation below 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation (Longest)</measure>
    <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
    <description>Longest time below saturation of 90% (the number of seconds elapsed between the start of a period in which the pulse oximeter saturation fell below 90% and the return above 90%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to General Anesthesia</measure>
    <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
    <description>Patients in which the procedure could not be completed without conversion to general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>After the bronchoscopy procedure only</time_frame>
    <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopist Satisfaction</measure>
    <time_frame>After the bronchoscopy procedure only</time_frame>
    <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine load</intervention_name>
    <description>Dexmedetomidine 1 µg/kg prior to bronchoscopy</description>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Precedex</other_name>
    <other_name>Dexmedetomidine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine load</intervention_name>
    <description>Ketamine 30 mg bolus prior to bronchoscopy</description>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
    <other_name>Calypsol</other_name>
    <other_name>Ketamin</other_name>
    <other_name>Ketaminol</other_name>
    <other_name>Ketanest</other_name>
    <other_name>Tekam</other_name>
    <other_name>Vetalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam load</intervention_name>
    <description>2 mg bolus prior to bronchoscopy</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl load</intervention_name>
    <description>50 µg bolus prior to bronchoscopy</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Abstral</other_name>
    <other_name>Actiq</other_name>
    <other_name>Fentora</other_name>
    <other_name>Onsolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine maintenance</intervention_name>
    <description>0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)</description>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Precedex</other_name>
    <other_name>Dexmedetomidine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine maintenance</intervention_name>
    <description>8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)</description>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
    <other_name>Calypsol</other_name>
    <other_name>Ketamin</other_name>
    <other_name>Ketaminol</other_name>
    <other_name>Ketanest</other_name>
    <other_name>Tekam</other_name>
    <other_name>Vetalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam demand</intervention_name>
    <description>0.5 mg demand bolus at discretion of pulmonologist</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl demand</intervention_name>
    <description>12.5 µg demand bolus at discretion of pulmonologist</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Abstral</other_name>
    <other_name>Actiq</other_name>
    <other_name>Fentora</other_name>
    <other_name>Onsolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benadryl demand</intervention_name>
    <description>25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>dexmedetomidine and ketamine</arm_group_label>
    <other_name>Diphenhydramine Hcl</other_name>
    <other_name>Aler-Dryl</other_name>
    <other_name>Banophen</other_name>
    <other_name>Ben Tann</other_name>
    <other_name>Bromanate AF</other_name>
    <other_name>Diphen</other_name>
    <other_name>Diphenadryl</other_name>
    <other_name>Diphenhist</other_name>
    <other_name>Dytan</other_name>
    <other_name>Unisom</other_name>
    <other_name>Sominex</other_name>
    <other_name>Silphen</other_name>
    <other_name>Siladryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over the age of 18 scheduled for elective flexible bronchoscopy in the
             endoscopy suite or OR of HUP

        Exclusion Criteria:

          -  History of inability to complete bronchoscopy attributable to inadequate sedation

          -  Requiring more than 2 LPM supplemental oxygen to maintain SaO2 &gt; 90%

          -  History of allergy to study medications

          -  Pregnancy

          -  A history of psychosis

          -  Any condition deemed likely by the pulmonologist or anesthesiologist to pose a
             significant risk due to elevation of blood pressure, including cerebral/aortic
             aneurysm, and or ischemic cardiovascular disease

          -  Bradydysrhythmia deemed significant by the anesthesiologist or pulmonologist

          -  A diagnosis of significant renal or hepatic impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff E Mandel, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yarmus LB, Akulian JA, Gilbert C, Mathai SC, Sathiyamoorthy S, Sahetya S, Harris K, Gillespie C, Haas A, Feller-Kopman D, Sterman D, Lee HJ. Comparison of moderate versus deep sedation for endobronchial ultrasound transbronchial needle aspiration. Ann Am Thorac Soc. 2013 Apr;10(2):121-6. doi: 10.1513/AnnalsATS.201209-074OC.</citation>
    <PMID>23607840</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <results_first_submitted>August 29, 2018</results_first_submitted>
  <results_first_submitted_qc>October 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2018</results_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bronchoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the practices of the pulmonologist sub investigators by the principal investigator</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Nebulized lidocaine 2% (maximum dose 200 mg) will be administered for 20 minutes.
Following nebulization, syringe A (placebo) will be given at a rate of 1 µg/kg (based on a concentration of 4 µg/ml) for 10 minutes. Supplemental topical anesthesia will be administered by the pulmonologist during this time.
After step 2, syringe B (midazolam 2 mg and fentanyl 50 µg) will be administered by the anesthesiologist. The infusion rate of syringe A (placebo) will be decreased to 0.7 µg/kg/hr. Syringe C (placebo) will be infused at 4 µg/kg/min (based on 10 mg/ml concentration)
Boluses of 0.5 mg midazolam and 12.5 µg fentanyl will be administered by the pulmonologist from syringe D as needed for patient comfort. Syringe E (benadryl 25 mg) will be administered in entirety by the anesthesiologist after the 6th and 16th bolus of midazolam/fentanyl.
placebo + Standard of Care of midazolam and fentanyl: Control Saline 50 ml Midazolam 2 mg + Fentanyl 50 µg Saline 20 ml Midazolam 1</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine and Ketamine</title>
          <description>Nebulized lidocaine 2% (maximum dose 200 mg) will be administered for 20 minutes.
Following nebulization, syringe A (dexmedetomidine) will be given at a rate of 1 µg/kg (based on a concentration of 4 µg/ml) for 10 minutes. Supplemental topical anesthesia will be administered by the pulmonologist during this time.
After step 2, syringe B (ketamine 30 mg) will be administered by the anesthesiologist. The infusion rate of syringe A (dexmedetomidine) will be decreased to 0.7 µg/kg/hr. Syringe C (ketamine) will be infused at 4 µg/kg/min (based on 10 mg/ml concentration)
Boluses of 0.5 mg midazolam and 12.5 µg fentanyl will be administered by the pulmonologist from syringe D as needed for patient comfort. Syringe E (benadryl 25 mg) will be administered in entirety by the anesthesiologist after the 6th and 16th bolus of midazolam/fentanyl.
dexmedetomidine and ketamine Study Medication: Experimental Dexmedetomidine 200 µg in 50 ml Ketamine 30 mg Ketamine 200 mg in 20 ml M</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo + Standard of Care of midazolam and fentanyl</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine and Ketamine</title>
          <description>dexmedetomidine and ketamine + Standard of Care of midazolam and fentanyl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="13.2"/>
                    <measurement group_id="B2" value="61.2" spread="14.9"/>
                    <measurement group_id="B3" value="59.88" spread="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decreased Minute Ventilation</title>
        <description>An initial baseline minute ventilation estimate was obtained via calibrated respiratory impedance plethysmography bands. Subsequent minute ventilation was normalized to this value. Values exceeding 100% were excluded from analysis, as these typically reflected a period of hyperpnea subsequent to relief of airway obstruction by chin lift or jaw thrust.</description>
        <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Decreased Minute Ventilation</title>
          <description>An initial baseline minute ventilation estimate was obtained via calibrated respiratory impedance plethysmography bands. Subsequent minute ventilation was normalized to this value. Values exceeding 100% were excluded from analysis, as these typically reflected a period of hyperpnea subsequent to relief of airway obstruction by chin lift or jaw thrust.</description>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.736" lower_limit="0.592" upper_limit="0.848"/>
                    <measurement group_id="O2" value="0.764" lower_limit="0.592" upper_limit="0.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No data available for power analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.028</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Fentanyl</title>
        <description>Total fentanyl dose delivered during the procedure</description>
        <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fentanyl</title>
          <description>Total fentanyl dose delivered during the procedure</description>
          <units>µg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="87.5" upper_limit="188.4"/>
                    <measurement group_id="O2" value="68.75" lower_limit="21.9" upper_limit="103.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>See reference power analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>43.75</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>units are µg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Midazolam</title>
        <description>Total midazolam delivered during procedure</description>
        <time_frame>Duration of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Midazolam</title>
          <description>Total midazolam delivered during procedure</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="2.75" lower_limit="0.9" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>See reference for power analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.75</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>units are mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desaturation (Cumulative)</title>
        <description>Cumulative time below saturation of 90% - the total number of seconds that the pulse oximeter reported a saturation below 90%</description>
        <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Desaturation (Cumulative)</title>
          <description>Cumulative time below saturation of 90% - the total number of seconds that the pulse oximeter reported a saturation below 90%</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="8.5" upper_limit="117.5"/>
                    <measurement group_id="O2" value="40" lower_limit="3.8" upper_limit="170.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desaturation (Longest)</title>
        <description>Longest time below saturation of 90% (the number of seconds elapsed between the start of a period in which the pulse oximeter saturation fell below 90% and the return above 90%)</description>
        <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Desaturation (Longest)</title>
          <description>Longest time below saturation of 90% (the number of seconds elapsed between the start of a period in which the pulse oximeter saturation fell below 90% and the return above 90%)</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="5" upper_limit="43.5"/>
                    <measurement group_id="O2" value="18" lower_limit="3" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conversion to General Anesthesia</title>
        <description>Patients in which the procedure could not be completed without conversion to general anesthesia</description>
        <time_frame>During the bronchoscopy procedure only, 58.5 minutes average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Conversion to General Anesthesia</title>
          <description>Patients in which the procedure could not be completed without conversion to general anesthesia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
        <time_frame>After the bronchoscopy procedure only</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopist Satisfaction</title>
        <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
        <time_frame>After the bronchoscopy procedure only</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo + Standard of Care of midazolam and fentanyl</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine and Ketamine</title>
            <description>dexmedetomidine and ketamine + Standard of Care (Midazolam + fentanyl)</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopist Satisfaction</title>
          <description>Satisfaction rated by 10 point Likert scale (0 = Totally dissatisfied, 10 = Totally satisfied)</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5.5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE data was collected over a 2 year period from the enrollment date for each participant .</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo + Standard of Care (midazolam and fentanyl)</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine and Ketamine</title>
          <description>dexmedetomidine and ketamine + Standard of Care (midazolam + fentanyl)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The presence of an anesthesiologist may have affected the aggressiveness of the pulmonologists in administering sedation.
Alterations in the study drug were not permitted; an open label study might find larger differences in respiratory measures</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeff E Mandel MD MS</name_or_title>
      <organization>Department of Anesthesiology &amp; Critical Care</organization>
      <phone>2156150553</phone>
      <email>mandelj@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

